Tag: 200-300

On March 14, 1995, Komamura, Tawara; Kato, Katsunori; Tanaka, Tatsuo published a patent.Application of 28489-43-2 The title of the patent was Aminopicoline-derived cyan dye and thermal-transfer printing material. And the patent contained the following:

The dye comprise cyano structure I [X = NR3R4, OH; R1 = H, halo, monovalent substitute; R2 = (substituted) aliphatic or aromatic group; R3, R4 = (substituted) alkyl, alkenyl aryl, aralkyl, cycloalkyl; substitutes of R3, R4 may form ring with R1; Y1 and/or Y2 = N, other is C]. The thermal-transfer printing material includes a colorant layer containing I associated with a binder. The dye, e.g., I (X = NEt2, Y1 = C, Y2 = N; R1 = 2-Me, R2 = CMe3), is prepared The experimental process involved the reaction of N,N-DIethyl-6-methyl-5-nitro-2-pyridinamine(cas: 28489-43-2).Application of 28489-43-2

The Article related to cyano dye thermal transfer printing, aminopicoline derived cyano dye printing, Radiation Chemistry, Photochemistry, and Photographic and Other Reprographic Processes: Impact and Nonimpact Printing, Platemaking and other aspects.Application of 28489-43-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On July 31, 2008, Diehl, Donald R.; Eiff, Shari L.; Landry-Coltrain, Christine J.; Russo, Gary M. published a patent.Related Products of 28489-43-2 The title of the patent was Stabilized dyes for thermal dye transfer materials. And the patent contained the following:

The present invention relates to a cyan dye donor element for thermal transfer imaging comprising a support having thereon a dye layer comprising a mixture of at least two cyan dyes dispersed in a polymeric binder, wherein at least one of the at least two cyan dyes is a light stabilizing dye represented by Formula I and a thermal image recording method utilizing the same cyan dye donor element, wherein R1 and R2 are substituted or unsubstituted alkyl, cycloalkyl, or aryl, or combine to form a carbocyclic or heterocyclic ring; R3 is hydrogen, halogen, alkoxy, substituted or unsubstituted alkyl, NHCOR1, NHSO2R1, or combine s with either R1 or R2 to form a carbocyclic or heterocyclic ring; X is halogen; Y is alkyl; Z is carbon or nitrogen; J is NHCOR4; R4 is R5Phenyl(OR7)m; R5 is -(CHR6)n- or -(CH2)pO-; R6 is hydrogen, substituted or unsubstituted alkyl; R7 is substituted or unsubstituted alkyl, carbocycle or heterocycle; m is 2-5; n is 0-6; p is 2-5; the formula weight of R4 does not exceed 230. The present invention also relates to a cyan ink-jet dye comprising a light stabilizing cyan dye represented by Formula I. The experimental process involved the reaction of N,N-DIethyl-6-methyl-5-nitro-2-pyridinamine(cas: 28489-43-2).Related Products of 28489-43-2

The Article related to stabilized dye thermal transfer sheet, Radiation Chemistry, Photochemistry, and Photographic and Other Reprographic Processes: Impact and Nonimpact Printing, Platemaking and other aspects.Related Products of 28489-43-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On October 12, 1977, Schmidtchen, Franz P.; Rapoport, Henry published an article.Reference of 2-Bromo-5,6-dimethoxy-3-methylpyridine The title of the article was Polyprenylpyridinols. Synthesis of piericidin analogs. And the article contained the following:

The piericidin A analogs I (n = 1, 2, 3, 9) and II were prepared for structure-activity studies on coenzyme Q inhibitors. To prepare the nucleus, 3-methoxyacetylamino-2-methylacrylonitrile was cyclized to a 4-amino-2-pyridone which Me3O+ BF4- converted to the 4-amino-2,3-dimethoxypyridine. Bromination of the acylated amine formed the 6-bromo derivative in which the 4-amino group was then replaced by hydroxy and the latter blocked by conversion to its benzyl ether with a benzylisourea. Transmetalation now gave the 6-lithio compound which was coupled with various prenyl bromides, leading to introduction of all trans polyprenyl side chains. The final 4-pyridinols were formed on selective debenzylation with butyl mercaptide. All the polyprenylpyridinols inhibited coenzyme Q electron transport to some extent, with the farnesyl analog having the same activity as piericidin A. The experimental process involved the reaction of 2-Bromo-5,6-dimethoxy-3-methylpyridine(cas: 64837-91-8).Reference of 2-Bromo-5,6-dimethoxy-3-methylpyridine

The Article related to piericidin a analog synthesis, pyridinol polypropenyl, prenylpyridinol preparation coenzyme q inhibitor, coenzyme q inhibitor, polyprenylpyridinol preparation coenzyme inhibitor and other aspects.Reference of 2-Bromo-5,6-dimethoxy-3-methylpyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On September 25, 2014, Schwiebert, Erik; Streiff, John; Dixon, John; Gao, Hongwu published a patent.Computed Properties of 25813-24-5 The title of the patent was Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders. And the patent contained the following:

The invention relates to coumarin derivatives of formula I or pharmaceutically acceptable salts or prodrugs thereof as novel CFTR corrector compounds that are effective in rescuing halide efflux, delF508-CFTR protein processing, and apical functional chloride ion transport in a cell are provided. Coumarin derivatives of formula I or pharmaceutically acceptable salts or prodrugs thereof, wherein R1, R2, R3, R4, X, and Y are as defined in the disclosure, are claimed. Example compounds such as II were prepared by multistep synthesis and evaluated in vitro and in vivo for their activity as CFTR correctors (data shown). Also provided are methods for treating protein folding disorders (e.g., cystic fibrosis and chronic obstructive pulmonary diseases). The methods include administering a CFTR corrector compound or pharmaceutically acceptable salt or prodrug thereof. Methods of rescuing halide efflux in a cell, correcting a processing defect of a delF508-CFTR protein in a cell, and correcting functional delF508-CFTR chloride channels in a cell are also provided. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Computed Properties of 25813-24-5

The Article related to coumarin preparation cftr corrector chronic obstructive pulmonary disease treatment, Heterocyclic Compounds (One Hetero Atom): Benzopyrans (Including Coumarins, Isocoumarins, Chromones, Benzopyrones, Dibenzopyrans, and Other Arenopyrans) and other aspects.Computed Properties of 25813-24-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Maity, Ayan; Anderson, Bryce Lane; Deligonul, Nihal; Gray, Thomas G. published an article in 2013, the title of the article was Room-temperature synthesis of cyclometalated iridium(III) complexes: kinetic isomers and reactive functionalities.Reference of 2-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine And the article contains the following content:

Cyclometalated iridium(III) complexes have been prepared in high yields from base-assisted transmetalation reactions of cis-bis(aquo)iridium(III) complexes with boronated aromatic proligands. Reactions proceed at room temperature Potassium hydroxide and potassium phosphate are effective supporting bases. Kinetic, meridional isomers are isolated because of the mildness of the new technique. Syntheses are faster with KOH, but the gentler base K3PO4 broadens the reaction’s scope. Complexes of chelated ketone, aldehyde, and alc. complexes are reported that bind iridium through formally neutral oxygen and formally anionic carbon. The new complexes luminesce with microsecond-scale(coating) lifetimes at 77 K and nanosecond-scale lifetimes at room temperature; emission quenches in air. Two complexes, an aldehyde and its reduced (alc.) derivative, are crystallog. characterized. Their bonding is examined with d.-functional theory calculations Time-dependent computations suggest that the Franck-Condon triplet states of these complexes have mixed orbital parentage, arising from one-particle transitions that mingle through CI. The experimental process involved the reaction of 2-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine(cas: 1349171-28-3).Reference of 2-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine

The Article related to phenylpyridine phenylpyrazole phenylquinoline benzothienylpyridine cyclometalated iridium preparation luminesce, crystal mol structure difluorophenylpyridine cyclometalated iridium formyltolyl complex and other aspects.Reference of 2-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Sarkar, Suman De; Kumar, N. Y. Phani; Ackermann, Lutz published an article in 2017, the title of the article was Ruthenium(II) Biscarboxylate-Catalyzed Borylations of C(sp2)-H and C(sp3)-H Bonds.Quality Control of 2-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine And the article contains the following content:

Versatile borylations of C(sp2)-H and C(sp3)-H were achieved with Ru(II) biscarboxylate complexes as catalysts. The robust nature of the Ru(II) catalyst enabled C(sp3)-H borylation on pyrrolidines, piperidines, aromatic compounds and azepanes with ample scope and excellent positional selectivity control. The experimental process involved the reaction of 2-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine(cas: 1349171-28-3).Quality Control of 2-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine

The Article related to ruthenium catalyzed borylation benzene pyrrolidine piperidine azepane, monoborylated arene heterocycle pyrrolidine piperidine azepane preparation, c−h activation, alkanes, boron, mechanism, ruthenium and other aspects.Quality Control of 2-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On November 20, 1997, Ankersen, Michael; Stidsen, Carsten Enggaard; Andersen, Henrik Sune published a patent.HPLC of Formula: 199522-66-2 The title of the patent was Preparation of thioureas and guanidines as somatostatin agonists and antagonists. And the patent contained the following:

The title compounds [I and II; m = 2-6; n = 1-3; p = 1-6; R1, R2 = H, (un)substituted C1-6 alkyl; X = S, O, NH, NC(O)Ph, N(CN); A, B, D = (un)substituted aryl, heteroaryl] and their salts, useful for treating medical disorders related to binding to human somatostatin receptor subtypes, were prepared and formulated. Thus, reaction of N-(4-bromobenzyl)-N-(3-isothiocyanatopropyl)-N-(pyridin-2-yl)amine and 3-(1-triphenylmethylimidazol-4-yl)propylamine in CHCl3 followed by treatment of the triphenylmethyl intermediate with HCl afforded 80% III.2HCl. Compounds I are effective at 0.001-50 mg/kg/day. The experimental process involved the reaction of N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine(cas: 199522-66-2).HPLC of Formula: 199522-66-2

The Article related to somatostatin agonist antagonist thiourea guanidine preparation, thiourea preparation formulation somatostatin agonist antagonist, guanidine preparation formulation somatostatin agonist antagonist and other aspects.HPLC of Formula: 199522-66-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On December 29, 2005, Delorme, Daniel; Woo, Soon Hyung; Vaisburg, Arkadii; Moradei, Oscar; Leit, Silvana; Raeppel, Stephane; Frechette, Sylvie; Bouchain, Giliane published a patent.Category: pyridine-derivatives The title of the patent was Preparation of triazinyl and other carboxamides as inhibitors of histone deacetylase. And the patent contained the following:

The invention provides compounds and methods for inhibiting histone deacetylase enzymic activity. Such compounds include carboxamides I [Cy2 = (un)substituted cycloalkyl, aryl, heteroaryl, heterocyclyl (each of which is optionally fused to one or two aryl or heteroaryl rings, or to one or two (un)saturated cycloalkyl or heterocyclic rings); X1 = a bond, M1L2M1, L2M2L2 (wherein L2 = a bond, alkylene, alkenylene, alkynylene; M1 = O, S, SO, NHCO, etc.; M2 = M1, heteroarylene, heterocyclylene); Ar2 = (un)substituted (hetero)arylene; R5, R6 = H, alkyl, aryl, aralkyl; q = 0-1; Ay2 = (un)substituted 5-6 membered cycloalkkyl, heterocyclyl or heteroaryl substituted with an amino or hydroxy moiety; with provisos] which were prepared and claimed. E.g., a multi-step synthesis of II, starting from Me 4-(aminomethyl)benzoate.HCl, was given. The invention also provides compositions and methods for treating cell proliferative diseases and conditions. Antineoplastic effects of some I are illustrated for colorectal, pulmonary and pancreatic neoplasms; also the combined antineoplastic effect of histone deacetylase inhibitors and histone deacetylase antisense oligonucleotides on tumor cells in vivo was demonstrated. Although the methods of preparation are not claimed, hundreds of example preparations are included. The experimental process involved the reaction of N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine(cas: 199522-66-2).Category: pyridine-derivatives

The Article related to carboxamide preparation inhibitor histone deacetylase hdac proliferative disease antitumor, triazinyl carboxamide preparation inhibitor histone deacetylase proliferative disease antitumor and other aspects.Category: pyridine-derivatives

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On January 29, 2015, Le Tiran, Arnaud; Le Diguarher, Thierry; Starck, Jerome-Benoit; Henlin, Jean-Michel; De Nanteuil, Guillaume; Geneste, Olivier; Davidson, James Edward Paul; Murray, James Brooke; Chen, I-Jen published a patent.Synthetic Route of 908267-63-0 The title of the patent was New indolizine carboxamide derivatives, their preparation as pro-apoptotic and antitumor agents and their pharmaceutical compositions containing them. And the patent contained the following:

Indolizine and indolizine derivatives, especially 5,6,7,8-tetrahydroindolizine optionally substituted with an NH2 group, 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine optionally substituted with a Me group and pyrrolo[1,2-a]pyrimidine derivatives, e.g., I•HCl, were prepared as inducers of caspase activity and apoptosis for treating neoplasm. Thus, I•HCl was prepared by a multi-step procedure starting from II (preparation given) and (3R)-3-methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride (preparation given). I•HCl was evaluated for its ability to induce caspase activity and therefore apoptosis in vitro and in vivo and for its ability to inhibit the Bcl-2 protein. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Synthetic Route of 908267-63-0

The Article related to indolizine preparation antitumor proapoptotic agent inducer caspase activity apoptosis, pyrrolopyrazine pyrrolopyrimidine indolizine carboxamide preparation antitumor proapoptotic agent and other aspects.Synthetic Route of 908267-63-0

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On January 30, 2015, Le Tiran, Arnaud; Le Diguarher, Thierry; Starck, Jerome-Benoit; Henlin, Jean-Michel; De Nanteuil, Guillaume; Geneste, Olivier; Davidson, James Edward Paul; Murray, James Brooke; Chen, I-Jen published a patent.HPLC of Formula: 908267-63-0 The title of the patent was New indolizine carboxamide derivatives, their preparation as pro-apoptotic and antitumor agents and their pharmaceutical compositions containing them. And the patent contained the following:

Indolizine and indolizine derivatives, especially 5,6,7,8-tetrahydroindolizine optionally substituted with an NH2 group, 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine optionally substituted with a Me group and pyrrolo[1,2-a]pyrimidine derivatives, e.g., I•HCl, were prepared as inducers of caspase activity and apoptosis for treating neoplasm. Thus, I•HCl was prepared by a multi-step procedure starting from II (preparation given) and (3R)-3-methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride (preparation given). I•HCl was evaluated for its ability to induce caspase activity and therefore apoptosis in vitro and in vivo and for its ability to inhibit the Bcl-2 protein. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).HPLC of Formula: 908267-63-0

The Article related to indolizine preparation antitumor proapoptotic agent inducer caspase activity apoptosis, pyrrolopyrazine pyrrolopyrimidine indolizine carboxamide preparation antitumor proapoptotic agent and other aspects.HPLC of Formula: 908267-63-0

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem